12:00 AM
Aug 05, 2013
 |  BioCentury  |  Finance

mAbs for the masses

Harbour: Small A round enough to compete with transgenic mouse platform
mAbs for the masses

Even though Harbour Antibodies B.V. is one of at least three biotechs seeking to broadly out-license their transgenic mouse platforms, Atlas Venture was attracted to the deal because the small investment gives the VC a stake in a commercially ready platform.

Atlas was the sole investor in last week's €2.5 million ($3.3 million) series A round.

Harbour also announced a deal giving Pfizer Inc. (NYSE:PFE) a non-exclusive license to the biotech's H2L2 mice. The company...

Read the full 378 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >